RxDoctor Payments Data

Sandra Mazzella

Nurse Practitioner · Huntingdon Valley, PANPI 1205397411

Payments from drug & device makers

$4,871in general payments, 2019–2025

Across 226 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$915
  • AbbVie$796
  • Pfizer$371
  • AstraZeneca$274
  • Teva Pharmaceuticals USA, Inc.$263
  • SK Life Science, Inc.$263
  • plus $2K from 29 others

What the payments were for

  • Consulting fees$1503%
  • Food & beverage$4,67696%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,871 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$20,700
Medicare patients
134
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate43$61,349
TopamaxTopiramate19$34,808
Aimovig AutoinjectorErenumab-Aooe32$27,767
Ajovy AutoinjectorFremanezumab-Vfrm24$18,625
DilantinPhenytoin Sodium Extended20$5,215
Levetiracetam144$4,151
Memantine Hcl49$2,826
Lacosamide22$2,763
Carbidopa-LevodopaCarbidopa/Levodopa102$2,668
Carbidopa-Levodopa ErCarbidopa/Levodopa41$2,626
Pyridostigmine Bromide22$2,242
Levetiracetam ErLevetiracetam17$1,995
Sumatriptan Succinate18$1,926
Rasagiline Mesylate17$1,398
Gabapentin82$1,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Dilantin$371$66,56463 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$121$2,24222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Huntingdon Valley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →